Moderna melanoma vaccine data misses lofty expectations, shares sink

Moderna's melanoma vaccine reduced risk of recurrence or death by 58%, but this fell short of Wall Street's high expectations, triggering a share price decline. The efficacy is strong but the market reaction reflects pricing of a more favorable outcome. This matters as it signals potential volatility in biotech valuations tied to clinical data releases.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works